Cholecystokinin research: CCK1R/CCK2R signaling, trafficking, and assay design

1) “CCK” is not a complete reagent identity

Cholecystokinin is synthesized as a larger precursor and processed into multiple C-terminally amidated peptides. CCK-58, CCK-33, CCK-22, and CCK-8 retain a shared bioactive C terminus, but they are not interchangeable analytical standards. Laboratories should report the complete sequence, molecular form, sulfation state, terminal chemistry, counterion, peptide content, purity, lot, solvent, and handling history. “CCK-8” is still ambiguous unless the tyrosine is explicitly identified as sulfated or nonsulfated.

The two human receptors are CCK1R, encoded by CCKAR, and CCK2R, encoded by CCKBR. Both are class A GPCRs, but their ligand discrimination and transducer profiles differ. CCK2R also recognizes gastrin peptides and is therefore historically called the gastrin receptor. A response in a native preparation cannot be assigned to one subtype solely because CCK was added; receptor expression, selective controls, and genetic attribution are needed.

Structural work resolved sulfated CCK-8 bound to human CCK1R–Gs and CCK2R–Gq complexes, along with selective agonist complexes. The receptors shared the canonical seven-transmembrane architecture while presenting distinct peptide-contact and G-protein interfaces.^[1] Those structures are powerful mechanistic models, but their stabilized constructs, tags, truncated tails, insect-cell expression, and engineered transducers should be documented before translating structural contacts into a live-cell assay.

2) Tyrosine sulfation changes receptor-subtype pharmacology

Sulfation of the tyrosine seven residues from the C terminus is a defining variable for CCK1R. Mutagenesis of CCK1R Arg197 preserved antagonist binding yet severely reduced peptide binding and functional activation. In the same study, nonsulfated CCK showed roughly 800-fold lower affinity and 500-fold lower potency than sulfated CCK at wild-type CCK1R, supporting an ionic interaction between the ligand sulfate and receptor Arg197.^[2]

Later cryo-EM and functional experiments placed the sulfotyrosine in a positively charged CCK1R pocket involving N98 and R197. In contrast, the corresponding CCK2R pocket is more hydrophobic and discriminates much less strongly between sulfated and nonsulfated CCK. The structural study reported that both receptors can couple to Gq, whereas Gs coupling was evident for CCK1R; a set of intracellular receptor residues helped explain this transducer preference.^[1]

This asymmetry creates a useful control strategy. Run sulfated CCK-8, nonsulfated CCK-8, and a CCK2R-preferring gastrin comparator under matched conditions. The comparison can reveal reagent mislabeling, mixed receptor populations, or pathway amplification. It cannot substitute for direct chemical identity or receptor knockout. A dramatic potency loss after desulfation is consistent with CCK1R pharmacology, but assay reserve and receptor abundance can compress or expand the observed difference.

3) Resolve proximal signaling before interpreting downstream biology

Gq-mediated phospholipase C activation, inositol-phosphate production, and calcium mobilization provide a practical starting point for both receptors. Define extracellular calcium, dye-loading conditions, temperature, sampling rate, baseline correction, and whether the endpoint is peak height, area, or kinetic model. A transient calcium trace combines receptor activation, store release, influx, extrusion, and detector behavior; it is not a direct binding measurement.

CCK1R can also engage Gs and elevate cAMP in suitable systems. The 2022 structural study used cAMP accumulation and NanoBiT G-protein dissociation to validate receptor contacts and found that specific intracellular mutations could abolish CCK1R–Gs signaling while largely retaining Gq activity.^[1] This pathway separation shows why one readout cannot define total efficacy. Receptor density may expose weak coupling in recombinant cells, while native cells may constrain it through transducer abundance and membrane context.

Downstream ERK phosphorylation, secretion, transcription, or morphology should follow receptor and proximal-pathway validation. Use receptor-null or knockout cells, loss-and-rescue designs, and subtype-selective controls. Pharmacological inhibitors can localize a pathway, but each requires a vehicle control, toxicity assessment, and confirmation that it does not directly alter the reporter. When comparing Gq with Gs, match expression, exposure time, temperature, and reference agonist, then report both potency and maximal response rather than ranking ligands by EC50 alone.

4) Receptor movement depends on ligand, receptor, and measurement window

Agonist exposure can recruit arrestins, remove receptors from the surface, and change subsequent responsiveness. CCK1R experiments using fluorescent ligands found that CCK and a signaling-silent antagonist could both promote internalization into similar cellular regions, although only CCK caused visible arrestin translocation. Peptide competition and receptor-mutant experiments implicated an intracellular-loop region in antagonist-driven uptake.^[3] Occupancy-driven movement therefore should not automatically be labeled arrestin-biased signaling.

CCK2R studies combined surface labeling, confocal imaging, dominant-negative arrestins, and dynamin perturbation. Agonist-induced surface loss depended on dynamin and was strongly reduced when both beta-arrestin isoforms were functionally blocked. Different partial agonists produced unequal signaling and internalization, permitting pathway-dependent classifications in that specific expression system.^[4] Such findings require matched kinetics and a common reference agonist before being generalized as ligand bias.

Quantify surface and total receptor at baseline and multiple post-ligand times. Pair microscopy with an orthogonal surface assay, validate fluorescent ligand pharmacology against unlabeled peptide, and include receptor-null cells. After washout, measure surface recovery and functional rechallenge. Recovery may reflect recycling, new synthesis, ligand dissociation, degradation, or reporter reset; distinguish these mechanisms rather than treating renewed signaling as proof of recycling.

5) Measure intact peptide, not only nominal concentration

CCK peptides are susceptible to matrix-dependent degradation and surface loss. An HPLC study of human and rat plasma found multiphasic disappearance of sulfated and nonsulfated CCK-8. In human plasma, the faster component had reported half-lives of about 50 minutes for sulfated CCK-8 and 18 minutes for nonsulfated CCK-8; degradation was faster in rat plasma, and aminopeptidase inhibitors altered cleavage.^[5] These values are conditions-specific, but they demonstrate that species, sulfation, temperature, and inhibitors can change delivered exposure.

Immunoreactivity is not equivalent to intact bioactive peptide. Antibodies may recognize fragments or several CCK molecular forms, while a total-mass measurement may miss sulfation loss or isobaric changes. Qualify the analytical method for the exact form being studied. A fit-for-purpose LC–MS or chromatographic method should resolve intact peptide from major variants and establish extraction recovery, carryover, linearity, and matrix effects.

Run time-zero standards, vehicle blanks, peptide-only incubations, and matched samples from buffer, complete medium, and conditioned medium. Test planned temperatures, vessel materials, concentrations, and exposure times. Standardize preparation order and freeze–thaw history. Low-binding plastic may reduce adsorption but must be verified experimentally. If a labeled analog is used, compare binding, signaling, and recovery curves with unlabeled peptide because a label can alter receptor recognition, proteolysis, or intracellular routing.

6) A reproducible CCK receptor laboratory workflow

1. Specify the peptide. Record molecular length, full sequence, sulfation, amidation, content, counterion, lot, and handling history.
2. Qualify the model. Measure receptor-subtype transcript, surface protein, total protein, and proximal function in the chosen passage and assay window.
3. Validate recovery. Quantify intact peptide across matrix, vessel, temperature, concentration, and time.
4. Pilot kinetics. Define activation, desensitization, internalization, washout, recovery, and rechallenge intervals.
5. Run matched curves. Include sulfated and nonsulfated CCK-8, an appropriate subtype comparator, vehicle, receptor-null cells, and detector-range controls.
6. Resolve pathways. Combine genetic receptor attribution with direct G-protein or second-messenger measurements.
7. Test trafficking orthogonally. Pair quantitative surface measurement with imaging and total-receptor assessment.
8. Predefine analysis. State the curve model, kinetic metric, normalization, exclusions, replicate hierarchy, and statistics.

7) Evidence limits and common errors

• Do not write “CCK-8” without its sulfation state. The modification strongly changes CCK1R recognition.
• Do not infer receptor subtype from tissue name. Measure and perturb CCK1R and CCK2R in the tested preparation.
• Do not equate calcium EC50 with affinity. Calcium includes amplification, receptor reserve, and kinetic effects.
• Do not call internalization signaling. Occupancy can drive trafficking without the measured canonical pathway.
• Do not infer bias from unmatched endpoints. Use common references, matched conditions, kinetic coverage, and an appropriate quantitative model.
• Do not treat immunoreactivity as proof of intact CCK. Confirm molecular form and sulfation with a qualified separation method.
• Do not extrapolate cell or animal findings into self-use, treatment, performance, or anti-aging claims. Conclusions remain limited to the tested system.

A rigorous CCK experiment links an analytically defined peptide form to a measured receptor subtype, direct proximal signaling, and time-resolved receptor fate. That chain separates genuine pharmacology from reagent ambiguity, proteolysis, receptor reserve, assay amplification, and trafficking artifacts.